Introduction: A Dynamic Funding Environment Biotech fundraising in 2026 is far from uniform, but it’s gaining clarity. After years of wide swings in capital availability, investor focus is sharpening on

Introduction: Why JPM Week Still Sets the Biotech Agenda Every January, JPM Week in San Francisco does more than convene executives and investors—it quietly sets the direction for biotech innovation

Introduction: A More Disciplined Era for Biotech Startups The biotech sector is entering 2026 with a markedly different funding mood than the exuberant years of the early 2020s. Easy money,

The global regulatory landscape for biotechnology is in the midst of a major evolution driven by scientific advances, geopolitical concerns, sustainability priorities, and shifting public expectations. For biotech startups, this

2025 has been a landmark year for gene editing not because of hype, but because of real patients walking out of clinics, researchers refining the tools, and regulators beginning to

In a small lab in Zagreb, researchers quietly mapped 90 new genes tied to immunoglobulin, G (IgG) glycosylation. The finding may seem arcane, but for drug makers simply trying to

When algorithms become the lab’s new pipette, biology is rewriting its own rulebook. The New Alchemy Picture a lab where silico meets vivo, software whispers into petri dishes, and bits

🌱 When Hope Takes the Stage: Conferences, Votes & Voices in Cancer Biotech Last week, I sat in a packed ballroom in Chicago. A hush fell as the keynote speaker—an